Variables | Male BRCAm carriers (n = 52) |
---|---|
Age at diagnosis (y) | |
 < 40 | 4(7.7) |
 40–49 | 3(5.8) |
 50–59 | 15(28.8) |
 60–69 | 21(40.4) |
 70–79 | 8(15.4) |
 ≥ 80 | 1(1.9) |
Family history of tumor | |
 no | 35(67.3) |
 yes | 15(28.8) |
 unknown | 2(3.8) |
Diagnose of multiple tumors | |
 no | 48(92.3) |
 yes | 2(3.8) |
 unknown | 2(3.8) |
Anatomic site of tumor | |
 prostate | 19(36.5) |
 colon/rectum | 13(25.0) |
 stomach | 7(13.5) |
 lung | 4(7.7) |
 kidney | 2(3.8) |
 head and neck | 2(3.8) |
 breast | 1(1.9) |
 bladder | 1(1.9) |
 other | 3(5.8) |
Histology | |
 adenocarcinoma | 38(73.1) |
 mucinous adenocarcinoma | 3(5.8) |
 urothelial carcinoma | 3(5.8) |
 squamous cell carcinoma | 2(3.8) |
 undifferentiated carcinoma | 2(3.8) |
 neuroendocrine carcinoma | 2(3.8) |
 other | 3(5.8) |
TNM stage | |
 I | 1(1.9) |
 II | 6(11.5) |
 III | 15(28.8) |
 IV | 28(53.8) |
 unknown | 2(3.8) |
BRCA1/2 mutation | |
 BRCA1 only | 16(30.8) |
 germline | 3(5.8) |
 somatic | 13(25.0) |
 both germline and somatic | 0(0.0) |
 BRCA2 only | 33(63.5) |
 germline | 4(7.8) |
 somatic | 26 (50.0) |
 both germline and somatic | 3(5.7) |
 both BRCA1 and BRCA2 | 3(5.8)a |
MSI | |
 MSS | 26 (50.0) |
 MSI-H | 7(13.5) |
 unknown | 19(36.5) |
TMB | |
 low (< 10 muts/Mb) | 17 (32.7) |
 moderate (10–20 muts/Mb) | 2(3.8) |
 high (> 20 muts/Mb) | 14 (26.9) |
 unknown | 19(36.5) |
Surgery | |
 no | 17 (32.7) |
 yes | 34 (65.4) |
 unknown | 1(1.9) |
Endocrinotherapy | |
 no | 40 (76.9) |
 yes | 11 (21.2) |
 unknown | 1(1.9) |
Chemotherapy | |
 no | 16(30.8) |
 yes | 35(67.3) |
 unknown | 1(1.9) |
Radiotherapy | |
 no | 36 (69.2) |
 yes | 15(28.8) |
 unknown | 1(1.9) |
Immunotherapy | |
 no | 44 (84.6) |
 yes | 7(13.5) |
 unknown | 1(1.9) |
Targeted therapy | |
 no | 47 (90.4) |
 yes | 4(7.7) |
 unknown | 1(1.9) |
Tumor progression | |
 no | 29 (55.8) |
 yes | 22 (42.3) |
 unknown | 1(1.9) |
Survival | |
 alive | 41 (78.9) |
 deceased | 10 (19.2) |
 unknown | 1(1.9) |